[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1993

Interferon and Hillary Clinton

Author Affiliations

Department of Dermatology Yale University School of Medicine 500 LCI 333 Cedar St New Haven, CT 06510

Arch Dermatol. 1993;129(6):763-765. doi:10.1001/archderm.1993.01680270101014

On reading the article by Mostow et al1 in this issue of the Archives, it becomes apparent that several forces that will control our management of patients will converge on the issue of interferon for cutaneous T-cell lymphoma (CTCL). The New York Times (January 18, 1993:1) headline "New Standard for Drug Makers: Proving the Cure Is Worth the Cost" reflected Washington's interest in this and similar studies. Now, with an office in the White House, Hillary Clinton will take the lead in defining the integration of new therapies into the administration's health care policy. Prodding on this collision of interests is the revolution in T-cell biology that is bringing a hailstorm of biological insights into T-cell lymphoma faster than anyone can catch them or consider who should pay for them. These forces will encounter each other over the next few months, and therapy assessment will be a major issue.

First Page Preview View Large
First page PDF preview
First page PDF preview